N,N-di(2-guanidinylethyl)amine | 90010-56-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N-di(2-guanidinylethyl)amine
• 英文别名: Bis-<2-guanidino-aethyl>-amin；Bis-(2-guanidino-aethyl)-amin；Bis(2-guanidinoethyl)amine；2-[2-[2-(diaminomethylideneamino)ethylamino]ethyl]guanidine
• CAS: 90010-56-3
• 化学式: C₆H₁₇N₇
• 分子量: 187.248
• InChiKey: PDNVDHJCDRAOFQ-UHFFFAOYSA-N

物化性质

• 沸点：
  355.5±52.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -3.3
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  141
• 氢给体数：
  5
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N,N-di(2-guanidinylethyl)amine sulfate monohydrate 在 barium(II) hydroxide 作用下， 以 水 为溶剂， 生成 N,N-di(2-guanidinylethyl)amine
  参考文献：
  名称：

  [EN] METHODS AND COMPOSITIONS COMPRISING GUANIDINES FOR TREATING BIOFILMS
  [FR] MÉTHODES ET COMPOSITIONS COMPRENANT DES GUANIDINES DESTINÉS AU TRAITEMENT DE BIOFILMS

  摘要：

  描述了使用胍类物质治疗或减少生物膜、治疗与生物膜有关的疾病、促使生物膜解体以及预防生物膜形成的方法。

  公开号：

  WO2014078801A1

文献信息

• [EN] METHODS AND COMPOSITIONS COMPRISING GUANIDINES FOR TREATING BIOFILMS<br/>[FR] MÉTHODES ET COMPOSITIONS COMPRENANT DES GUANIDINES DESTINÉS AU TRAITEMENT DE BIOFILMS
  申请人：HARVARD COLLEGE

  公开号：WO2014078801A1

  公开（公告）日：2014-05-22

  Methods of treating or reducing biofilms, treating a biofilm-related disorder, triggering biofilm disassembly, and preventing biofilm formation using guanidines is described.

  描述了使用胍类物质治疗或减少生物膜、治疗与生物膜有关的疾病、促使生物膜解体以及预防生物膜形成的方法。
• [EN] PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION DE MONOMÈRES À FONCTION GUANIDINO
  申请人：3M INNOVATIVE PROPERTIES CO

  公开号：WO2014204763A1

  公开（公告）日：2014-12-24

  A process for preparing guanidino-functional, free radically polymerizable compounds comprises (a) combining (1) an amine compound comprising (i) at least one primary aliphatic amino group and (ii) at least one secondary aliphatic amino group, primary aromatic amino group, or secondary aromatic amino group, and (2) a guanylating agent; (b) allowing or inducing reaction of the amine compound and the guanylating agent to form a guanylated amine compound; (c) combining (1) the guanylated amine compound, and (2) a reactive monomer comprising (i) at least one ethylenically unsaturated group and (ii) at least one group that is reactive with an amino group; and (d) allowing or inducing reaction of the guanylated amine compound and the reactive monomer to form a guanidino-functional, free radically polymerizable compound.

  制备胍基功能自由基聚合化合物的过程包括(a)结合(1)包含(i)至少一个主链脂肪氨基团和(ii)至少一个次级链脂肪氨基团、主链芳香胺基团或次级芳香胺基团的胺基化合物和(2)胍基化试剂；(b)允许或诱导胺基化合物和胍基化试剂发生反应以形成胍基化胺基化合物；(c)结合(1)胍基化胺基化合物和(2)包含(i)至少一个乙烯不饱和基团和(ii)至少一个与氨基反应的基团的反应单体；(d)允许或诱导胍基化胺基化合物和反应单体发生反应以形成胍基功能自由基聚合化合物。
• Intranasal cyclic peptide formulations
  申请人：——

  公开号：US20010038824A1

  公开（公告）日：2001-11-08

  The present invention relates to a nasally administrable composition of a physiologically active cyclic peptide and pharmaceutically acceptable salts thereof that is prepared by homogeneously dispersing a physiologically active cyclic peptide such as antifungal cyclic peptides (aerothricins, echinocandin analogs, pneumocandin analogs, and aureobacidines), antibacterial cyclic peptides (e.g. vancomycin, daptomycin), cyclosporin A, lanreotide, vapreotide, vasopressin antagonist (U.S. Pat. No. 5,095,003) and eptifibatide in unique carrier, i.e. a physiologically acceptable powdery or crystalline carrier containing a water insoluble polyvalent metal carrier, or organic carrier having a mean particle size of 20 to 500 &mgr;m, in the presence or absence of an absorption enhancer and by homogeneously adsorbing onto the carrier, and its use for therapeutic treatment of disease such as systemic fungal infections by intranasal administration. The composition can be nasally administered in powder form.

  本发明涉及一种鼻腔可给药的生理活性环肽及其药学上可接受的盐的组合物，该组合物通过将生理活性环肽（如抗真菌环肽（气菌素、伊曲康定类似物、肺孢子菌素类似物和金黄色细菌素）、抗菌环肽（如万古霉素、达托霉素）、环孢霉素A、兰雷罗肽、瓦普雷罗肽、抗利尿激素拮抗剂（美国专利号5,095,003）和依普利贝肽）均匀分散在独特的载体中制备而成，即含有水不溶性多价金属载体或平均粒径为20至500微米的有机载体的生理上可接受的粉状或结晶载体中，存在或不存在吸收增强剂，通过均匀吸附到载体上，并用于通过鼻内给药治疗疾病，如系统真菌感染。该组合物可以以粉剂形式鼻腔给药。
• PROCESS FOR PREPARING GUANIDINO-FUNCTIONAL MONOMERS
  申请人：3M INNOVATIVE PROPERTIES COMPANY

  公开号：US20160096802A1

  公开（公告）日：2016-04-07

  A process for preparing guanidino-functional, free radically polymerizable compounds comprises (a) combining (1) an amine compound comprising (i) at least one primary aliphatic amino group and (ii) at least one secondary aliphatic amino group, primary aromatic amino group, or secondary aromatic amino group, and (2) a guanylating agent; (b) allowing or inducing reaction of the amine compound and the guanylating agent to form a guanylated amine compound; (c) combining (1) the guanylated amine compound, and (2) a reactive monomer comprising (i) at least one ethylenically unsaturated group and (ii) at least one group that is reactive with an amino group; and (d) allowing or inducing reaction of the guanylated amine compound and the reactive monomer to form a guanidino-functional, free radically polymerizable compound.

  制备含有胍基官能团、自由基聚合化合物的过程包括：（a）混合（1）一种胺化合物，该胺化合物包括（i）至少一个一级脂肪族氨基团和（ii）至少一个二级脂肪族氨基团、一级芳香族氨基团或二级芳香族氨基团，以及（2）一种胍基化试剂；（b）使胺化合物和胍基化试剂发生反应形成胍基化胺化合物；（c）混合（1）胍基化胺化合物和（2）一种反应单体，该反应单体包括（i）至少一个乙烯基不饱和基团和（ii）至少一个与氨基反应的基团；（d）使胍基化胺化合物和反应单体发生反应形成含有胍基官能团、自由基聚合化合物。
• Cationic bacteriochlorophyll derivatives and uses thereof
  申请人：YEDA RESEARCH AND DEVELOPMENT CO., LTD.

  公开号：EP2322173A1

  公开（公告）日：2011-05-18

  The invention provides cationic tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one positively charged group and/or at least one basic group that is converted to a positively charged group under physiological conditions, preferably Bchls having an onium group derived from a N-containing aliphatic or heterocyclic radical such as ammonium, guanidinium, imidazolium, pyridinium, and the like or a phosphonium, arsonium, oxonium, sulfonium, selenonium, telluronium, stibonium, or bismuthonium group, or a basic group that is converted to such onium groups under physiological conditions, said groups being bound to one or more of the positions 173, 133 and 32 of the Bchl molecule by ester or amide bond. The Bchls are useful for photodynamic therapy and diagnosis.

  本发明提供阳离子四环和五环细菌叶绿素衍生物（Bchls），含有至少一个带正电荷的基团和/或至少一个在生理条件下转化为带正电荷基团的碱性基团、胍、咪唑鎓、吡啶鎓等，或磷、砷、氧鎓、锍、硒、碲、锑或铋基团，或在生理条件下转化为此类鎓基团的碱性基团，所述基团通过酯键或酰胺键与 Bchl 分子的一个或多个位置 173、133 和 32 结合。Bchls 可用于光动力疗法和诊断。